AMERICAN SOCIETY OF CLINICAL ONCOLOGY
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1964-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.asco.org
RWJBarnabas Health and Rutgers Cancer Institute to Present 45 Groundbreaking Studies at ASCO 2025
• Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches.
• A notable multisite randomized trial demonstrated that problem-solving skills training significantly improved depression, anxiety, and quality of life in young adults newly diagnosed with cancer compared to standard care.
• New research revealed that patients living in both food and clinical trial deserts had 27% lower likelihood of breast cancer trial enrollment, highlighting how geographic and socioeconomic barriers impact cancer care access.
Cizzle Bio's CIZ1B Blood Test Could Save Medicare $518 Million Annually in Lung Cancer Screening
• New ASCO study reveals Cizzle Bio's CIZ1B biomarker blood test for early-stage lung cancer detection could save the U.S. Medicare program up to $518 million annually while improving screening accessibility.
• The CIZ1B test demonstrates 95% sensitivity for Stage I lung cancer detection with a 96% Negative Predictive Value, potentially reducing unnecessary biopsies and increasing early detection rates.
• Economic models project a 15% increase in screening participation among high-risk Medicare beneficiaries by eliminating barriers associated with traditional low-dose CT screening methods.
AI Tools Show Promise in Improving HER2 Breast Cancer Classification and Treatment Eligibility
• A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized.
• The Digital PATH Project, involving 31 partners including pharmaceutical companies and academic centers, validated AI diagnostic technologies using 1,100 breast cancer tissue samples to assess consistency in HER2 expression identification.
• AI tools particularly enhanced detection of HER2-low and HER2-ultralow expression levels, reducing misclassification by 24.4% and potentially expanding treatment eligibility for antibody-drug conjugates to patients previously classified as HER2-negative.
PharmaEssentia's Ropeginterferon Shows Promising Results in Phase 3 Trial for Essential Thrombocythemia
• PharmaEssentia will present positive Phase 3 SURPASS-ET trial results showing ropeginterferon alfa-2b-njft achieved significantly higher durable clinical response rates compared to anagrelide (42.9% vs. 6.0%; p=0.0001) in essential thrombocythemia patients.
• The trial demonstrated not only effective blood count control but also a measurable reduction in JAK2 mutation allele burden over 12 months, addressing an underlying disease mechanism that current treatments fail to target.
• Ropeginterferon alfa-2b-njft (marketed as BESREMi® for polycythemia vera) could potentially offer a new second-line treatment option for essential thrombocythemia, a rare blood disorder characterized by excessive platelet production.
FDA Greenlights Promontory Therapeutics' Phase 3 Trial Design for PT-112 in Metastatic Prostate Cancer
• Promontory Therapeutics has successfully completed an End of Phase 2 meeting with the FDA, reaching agreement on key aspects of a registrational Phase 3 trial for PT-112 in metastatic castration-resistant prostate cancer.
• The FDA approved the proposed dosing regimen, patient population, study comparator, and endpoints, with an interim analysis provision that could allow for drug approval before study completion.
• Preliminary clinical outcomes from the Phase 2 trial of PT-112 will be presented at the upcoming ASCO 2025 Annual Meeting on June 2nd, following recent presentation of immune response biomarker data at AACR 2025.
IQVIA and Sarah Cannon Research Institute Partner to Transform Global Oncology Clinical Trials
• IQVIA and SCRI Development Innovations have formed a strategic collaboration aimed at revolutionizing oncology clinical trials through improved operations, faster data delivery, and accelerated patient access to advanced therapies.
• The partnership combines IQVIA's global reach and experience managing 20% of U.S. oncology trials with SCRI's community oncology expertise and Accelero operational model, which streamlines trial activation and data collection.
• This collaboration creates a unified, efficient model for delivering oncology trials globally, reducing vendor complexity and operational hurdles while expediting the development of innovative cancer treatments.
Biodesix Presents New Data Showing Nodify Lung® Tests Improve Pulmonary Nodule Management
• New study of over 350,000 patients reveals significant gaps in lung nodule management, with approximately two-thirds receiving no clinical work-up after nodule discovery.
• Research presented at ISPOR 2025 shows concerning rates of mismanagement, with 60% of biopsies performed on benign nodules and 35% of malignant nodules receiving only follow-up CT scans.
• Real-world data from a safety-net hospital demonstrates how Biodesix's Nodify Lung® testing can guide clinical decisions through actionable results in pulmonary nodule risk stratification.
Weight Loss Injections Show Promising Anti-Cancer Effects Beyond Weight Reduction
• Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction.
• Scientists from the University of Manchester are designing a large-scale clinical trial involving tens of thousands of patients to further investigate GLP-1 agonists as cancer prevention tools.
• Experts believe these findings could herald a "new dawn" in preventative cancer medicine, potentially benefiting even non-obese individuals with high cancer risk factors.
FDA Advisory Committee Discusses Columvi Combination for Relapsed or Refractory DLBCL
• Genentech's Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin demonstrated a 41% reduction in risk of death for patients with relapsed or refractory diffuse large B-cell lymphoma in the Phase III STARGLO study.
• The FDA Oncologic Drugs Advisory Committee met to discuss the supplemental Biologics License Application for this combination therapy, focusing on the applicability of global trial results to U.S. patients.
• If approved, this first-of-its-kind bispecific antibody combination could provide a much-needed, off-the-shelf, fixed-duration treatment option for transplant-ineligible patients who currently face poor prognosis.
Agendia's BluePrint Test Shows Promise in Identifying Chemotherapy-Responsive Breast Cancer Subtypes
• New FLEX Study data reveals BluePrint molecular subtyping assay can identify Basal-type tumors among MammaPrint High Risk HR+ HER2- breast cancers that respond better to chemotherapy.
• Patients with Basal-type tumors showed higher pathological complete response rates following neoadjuvant chemotherapy compared to those with Luminal B tumors, supporting more personalized treatment approaches.
• The findings, to be presented at ESMO Breast Cancer 2025, demonstrate how BluePrint's 80-gene signature provides actionable insights that physicians are using to inform real-world treatment decisions.
Stanford Health Care Deepens Integration of Atropos Health's Real-World Evidence Platform into Clinical Workflow
• Stanford Health Care has expanded its partnership with Atropos Health to embed real-world evidence directly into clinical workflows and encounter notes, enhancing point-of-care decision making without disrupting physician workflow.
• The integration will work alongside Stanford's ambient AI provider, DAX from Microsoft, to generate evidence that helps clinicians finalize their notes while remaining within their existing EHR environment.
• This advancement builds on Stanford's multi-year collaboration with Atropos Health, which began as the "Green Button" research project at Stanford Medicine in 2011 and has evolved to support over 2,000 affiliated physicians.
Racial and Ethnic Disparities Persist in Pediatric Neuroblastoma Survival Despite Clinical Trial Access
• Black and Hispanic children with high-risk neuroblastoma experience significantly worse survival outcomes compared to white peers, even when treated in standardized clinical trials, according to new research from UT Southwestern Medical Center.
• The study, published in JAMA Network Open, found Hispanic children had nearly 80% higher risk of death after induction treatment, while both Black and Hispanic children showed lower survival rates in post-consolidation trials.
• Researchers found no significant racial or ethnic differences in care delivery or treatment delays, suggesting social determinants of health may play a crucial role in outcome disparities.
Personalis to Present New Data on NeXT Personal ctDNA Test for Early Cancer Detection at Major Oncology Conferences
• Personalis and academic collaborators will showcase new clinical data on their ultrasensitive NeXT Personal ctDNA assay at upcoming AACR and ASCO conferences, demonstrating its application across multiple cancer types.
• The VICTORI study will present preliminary results on post-surgical minimal residual disease detection in colorectal cancer, while the TRACERx collaboration will share findings from one of the largest ctDNA studies in early-stage lung cancer.
• New research will expand clinical evidence for NeXT Personal into neoadjuvant treatment settings for breast cancer and cervical cancer, supporting the company's mission to enable earlier detection of residual and recurrent cancer.
BRCA2 Mechanism Reveals Why PARP Inhibitors Work in Only Some Cancer Patients
• NYU Langone researchers have discovered that BRCA2 acts as a molecular shield preventing PARP1 from binding to DNA damage sites, explaining why PARP inhibitors are effective only in certain cancer patients.
• The study, published in Nature, used advanced single-molecule imaging to reveal how BRCA2 ensures RAD51 protein can access DNA repair sites instead of PARP1, preventing treatment-generated DNA breaks in resistant cancer cells.
• This breakthrough explains variable patient responses to PARP inhibitors like olaparib, which have shown effectiveness in pancreatic, prostate, breast, and ovarian cancers with BRCA mutations, pointing to the need for patient-specific tumor profiling.
REACH3 Trial Update: Ruxolitinib Shows Promising Efficacy in Steroid-Refractory Chronic GVHD
• Updated data from the REACH3 trial demonstrates significant efficacy of ruxolitinib in treating patients with steroid-refractory chronic graft-versus-host disease, according to Dr. Stephanie Lee.
• The JAK inhibitor shows promising results in the broader chronic GVHD population, potentially offering a new therapeutic option for patients who fail to respond to first-line steroid treatments.
• Clinical characteristics and molecular profiles are becoming increasingly important in personalizing JAK inhibitor selection for patients with conditions like myelofibrosis and chronic GVHD.
BioNTech's BNT327 Shows Promising 85% Response Rate in First-Line Treatment for Extensive-Stage SCLC
• BNT327, a bispecific antibody targeting both PD-L1 and VEGF-A, demonstrated an 85.4% confirmed response rate when combined with chemotherapy in extensive-stage small cell lung cancer patients.
• The phase 2 trial showed impressive disease control in 97.9% of patients, with 12-month overall survival rates of 72.7%, suggesting potential improvement over current standard treatments.
• Despite 86% of patients experiencing grade 3 or higher treatment-related adverse events, the safety profile was considered manageable with only 6% discontinuing treatment and no treatment-related deaths reported.
DSMB Recommends Continuation of BriaCell's Phase 3 Trial for Metastatic Breast Cancer Immunotherapy
• The independent Data Safety Monitoring Board has completed its second safety review of BriaCell's pivotal Phase 3 study, finding no safety concerns and recommending continuation without modifications.
• BriaCell's novel immunotherapy combines Bria-IMT with an immune checkpoint inhibitor for metastatic breast cancer patients, with the trial proceeding under FDA Fast Track Designation.
• Company executives highlight the positive safety profile as an encouraging step toward addressing the urgent medical need for effective treatments for metastatic breast cancer patients.
FDA Grants Orphan Drug Designation to BioInvent's BI-1808 for T-cell Lymphoma Treatment
• BioInvent's first-in-class anti-TNFR2 antibody BI-1808 receives FDA Orphan Drug Designation for treating T-cell lymphoma, providing development incentives and seven years of market exclusivity.
• Recent Phase 2a clinical trial data showed promising efficacy in cutaneous T-cell lymphoma patients, with three partial responses and one stable disease among four evaluable patients who had previously failed standard treatments.
• The designation supports BioInvent's strategy to develop novel immunomodulatory therapies for rare cancers, addressing the significant unmet need among approximately 3,000 new CTCL cases diagnosed annually in the United States.
Five-Year CROWN Trial Data Establishes Lorlatinib as First-line Standard for ALK+ NSCLC
• Extended follow-up data from the phase 3 CROWN trial demonstrates superior efficacy of lorlatinib over crizotinib, with median progression-free survival not yet reached at 60.2 months.
• Strategic dosing approach starting at 50mg and gradually increasing to manage neurocognitive side effects is recommended, differing from the standard 100mg daily dosing in prescribing information.
• Approximately 60% of patients may experience neurocognitive adverse events, requiring careful monitoring and proactive management through dose optimization.
Verastem Oncology to Present New LGSOC Treatment Data at SGO 2025 Annual Meeting
• Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission.
• The presentations include new subgroup analyses by KRAS mutational status, supporting the company's ongoing efforts to advance treatment options for RAS/MAPK pathway-driven cancers.
• The company's NDA for the avutometinib-defactinib combination therapy has received Priority Review from the FDA with a PDUFA date of June 30, 2025, for KRAS mutant LGSOC patients.
© Copyright 2025. All Rights Reserved by MedPath